Who are Mandated back ground therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Glimepiride/metformin fixed combination, oral hypoglycemic agents, Metformin cloridrate, medical nutrition therapy + metformin, Metformin Small Pack, Amlodipine plus Metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mandated-back-ground-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Mandated back ground therapy — Competitive Intelligence Brief

Mandated back ground therapy (Mandated back ground therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: biguanide. Area: Diabetes.

marketed biguanide Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Mandated back ground therapy (Mandated back ground therapy) — Sanofi. Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mandated back ground therapy TARGET	Mandated back ground therapy	Sanofi	marketed	biguanide
Glimepiride/metformin fixed combination	Glimepiride/metformin fixed combination	Handok Inc.	marketed	Sulfonylurea/biguanide combination	ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin)
oral hypoglycemic agents	oral hypoglycemic agents	Queen Elizabeth II Health Sciences Centre	marketed	Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)
Metformin cloridrate	Metformin cloridrate	University Magna Graecia	marketed	Biguanide	AMP-activated protein kinase (AMPK)
medical nutrition therapy + metformin	medical nutrition therapy + metformin	Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes	marketed	Combination therapy: dietary intervention + biguanide antidiabetic	AMP-activated protein kinase (AMPK) and hepatic glucose metabolism (metformin component)
Metformin Small Pack	Metformin Small Pack	GlaxoSmithKline	marketed	Biguanide	AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain
Amlodipine plus Metformin	Amlodipine plus Metformin	Third Military Medical University	marketed	Combination therapy: calcium channel blocker + biguanide antidiabetic	L-type voltage-gated calcium channels (amlodipine); AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (biguanide class)

Eli Lilly and Company · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mandated back ground therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/mandated-back-ground-therapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab